Graham Capital Management L.P. Raises Stock Position in Encompass Health Co. (NYSE:EHC)

Graham Capital Management L.P. grew its position in Encompass Health Co. (NYSE:EHC) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,750 shares of the company’s stock after buying an additional 1,067 shares during the period. Graham Capital Management L.P.’s holdings in Encompass Health were worth $3,302,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. purchased a new position in Encompass Health in the fourth quarter worth approximately $152,953,000. Norges Bank purchased a new position in shares of Encompass Health during the 4th quarter worth $100,637,000. Raymond James Financial Inc. acquired a new stake in shares of Encompass Health during the 4th quarter worth about $77,944,000. Jennison Associates LLC acquired a new position in Encompass Health in the fourth quarter valued at about $52,094,000. Finally, Farallon Capital Management LLC boosted its stake in Encompass Health by 15,266.7% during the fourth quarter. Farallon Capital Management LLC now owns 461,000 shares of the company’s stock worth $42,573,000 after buying an additional 458,000 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $135.00 price target (up from $116.00) on shares of Encompass Health in a research note on Monday, April 28th. StockNews.com upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday. Royal Bank of Canada lifted their price objective on Encompass Health from $110.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, April 28th. UBS Group boosted their price objective on Encompass Health from $117.00 to $130.00 and gave the company a “buy” rating in a report on Monday, April 28th. Finally, Barclays lifted their target price on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $120.86.

Insider Buying and Selling at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now directly owns 69,164 shares of the company’s stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the business’s stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president now directly owns 79,710 shares of the company’s stock, valued at approximately $9,149,910.90. This trade represents a 11.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,321 shares of company stock worth $2,142,452 over the last three months. Insiders own 2.00% of the company’s stock.

Encompass Health Stock Performance

Shares of Encompass Health stock opened at $116.45 on Friday. The business has a 50-day simple moving average of $103.44 and a 200-day simple moving average of $99.96. The company has a market cap of $11.74 billion, a PE ratio of 26.11, a P/E/G ratio of 2.31 and a beta of 0.91. Encompass Health Co. has a one year low of $82.74 and a one year high of $118.27. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.18. The business had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The company’s revenue was up 10.6% on a year-over-year basis. During the same period last year, the business earned $1.12 EPS. On average, equities research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.58%. The ex-dividend date is Tuesday, July 1st. Encompass Health’s payout ratio is 14.05%.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.